created HMPB/BLZ945/anti-SIRPα as a multifunctional immunotherapeutic in situ fibrin gel for addressing challenged caused by postoperative recurrence of HCC (Fig. 8A, B) [156]. The gene discussed is SIRPA; the disease is hepatocellular carcinoma.